PPT-≥ 18 years, HCV genotype 1-6

 18 years HCV genotype 16 HCV RNA gt 1 000 IUmL Treatmentnaïve TN or treatmentexperienced TE without DAA except SOF With or without cirrhosis Chronic kidney disease stage 3b 4 or 5 . Lineage 1 (2008). Genotype B5 . Lineage 2 (2012). Supplementary figure 2. 2003.82. 2010.44. 2004.31. Genotype . B4. Genotype . B1. Genotype . C4. Genotype . C2. Design. C-SCAPE . Study. : . grazoprevir. ± . elbasvir. ± RBV . in . genotypes. 2, 4, 5 or 6. Treatment-naïve . Genotype 2. , 4, 5, 6. Non-cirrhotic, . HCV . monoinfected. Brown . A. . . J . Hepatol. 3. Rd. International . HIV/Hepatitis . Coinfection. . Meeting. Durban SA. Marina B. Klein, MD, MSc FRCP. (C). Chronic. Viral . Illness. Service. McGill University . Health. . Centre. How times have changed. Feld JJ. NEJM . 2014;370:1594-1603. SAPPHIRE-I . Study. : . o. mbitasvir/paritaprevir/ritonavir. . + . d. asabuvir. . + . ribavirin. . for genotype 1. Treatment regimens. Co-formulated . ombitasvir. qd. Non-randomised. Open-label. N =. 21. W12. SVR. 12. NIAID . SYNERGY GT4. Kohli. A. Lancet Infect Dis. 2015 Sep;15(9):1049-54. ≥ 18 years. Chronic HCV Genotype 4. Treatment-naïve or experienced. ASTRAL-2*. Phase 3. . Treatment. . Naïve & Experienced. Foster GR, . et al. . N . Engl. J Med. . 2015. ;373:2608-17.. *Published in tandem with ASTRAL-3 Trial. Source: Foster GR, . et al. N . HCV RNA ≥ 1000 IU/mL. Treatment-naïve or treatment-experienced with IFN or PEG-IFN . .  RBV or SOF RBV ± PEG-IFN. Compensated . cirrhosis *. No HBV or HIV co-infection. Design. W12. EXPEDITION-1 . DSV . placebo. Randomisation*. Partial blind. 18-70 years. Chronic HCV infection. Genotype 1 . Treatment-naïve. HCV RNA > 10,000 IU/ml. No cirrhosis. No HBV or HIV co-infection. * Randomisation 1:2 if genotype 1a (PEARL-IV) ; . ASTRAL-1. Phase 3. . Treatment. . Naïve & Experienced. Feld JJ, . et al. . N . Engl. J Med. . 2015. ;373:2599-607.. Source: Feld . JJ. , et al. N . Engl. J Med. . 2015. ;373:2599-607.. Sofosbuvir-Velpatasvir. C-EDGE Treatment Naïve (TN). Phase 3. . Treatment. . Naïve. Zeuzem. S, . et al. . Ann Intern Med. 2015;163:1-13.. Source: . Zeuzem. S, et al. Ann Intern Med. 2015;163:1-13. .. Elbasvir-Grazoprevir. Strategies To Identify and Advance PWID HCV Patient Care. Linkage to C Care Program. . Imtiaz Alam, M.D.. Medical Director, Austin Hepatitis Center. Medical Director, . HepCare. Specialty Pharmacy. Hansen Dang,. 1,2*. Yee Hui Yeo,. 1*. Satoshi Yasuda,. 3. Chung-Feng Huang,. 4. Etsuko Iio,. 5. Charles Landis,. 6. Dae Won Jun,. 7. Masaru Enomoto,. 8. Eiichi Ogawa,. 9. Pei-. Chien. Tsai,. & . Update on HCV . blood bank protocol. . Overview - . diagnostic tests. Serologic . assays: . specific antibody to hepatitis C virus (anti-HCV). Molecular . assays: HCV nucleic acid . (. nucleic. Mandatory criteria: . Probability based sampling. Basic demographic information collected (age, gender, postcode). Ethical board approval . For other criteria see SPHERE-C . protocol. Is there any recent (<10 years) evidence from testing proxy populations (e.g. pregnant women/blood donors/emergency department attendees) or from sub-populations (regional studies/older age groups) that HCV RNA prevalence in the general population could be > 1%?.